The MMP-1, -2, and -3 promoter genotypes were successfully determined for 490 (97.4%), 486 (96.6%), and 470 (93.4%) of the CRC patients and 470 (99.9%), 467 (99.1%), and 452 (96.0%) of the control subjects, respectively. This evidence concerns the gene MMP1 and colorectal carcinoma.